The global respiratory disease testing market accounted for USD 3.44 billion in 2023 and is expected to reach at USD 5.65 billion by 2034 with a CAGR of 4.62% during the forecast period 2024-2034. Rising prevalence of respiratory diseases, increasing air pollution levels, heightened transmission of infections such as tuberculosis & hospital-acquired infections, surge in technological advancements, growing funding from diverse organizations & governments for various projects, rising focus on the development of new testing methods by companies, increasing adoption of imaging technologies such as Computed Tomography (CT) for diagnosing COPD, and growing introduction of innovative respiratory disease testing products are some of the key factors boosting the market growth.
Growing introduction of novel respiratory disease testing products is predicted to boost the market growth during the forecast period. The respiratory system, crucial for human survival, serves the essential function of breathing and contributes significantly to maintaining the body's blood pH balance, eliminating harmful waste, and regulating temperature. Disruption of its normal functions occurs with respiratory diseases, often triggered by inhaling harmful substances, smoking, or unhealthy habits. For instance, in May 2022, UK's QuantuMDx Group Limited, known for its groundbreaking point-of-care diagnostic solutions, has introduced its latest offering, the Q-POC SARS-CoV-2, Flu A/B & RSV Assay, aimed at respiratory panel testing. This launch signifies the company's broadening of its multiplex capabilities and commitment to delivering swift point-of-care testing options to its clientele.
By product, imaging tests was the highest revenue-grossing segment in the global respiratory disease testing market in 2023 owing to the growing trend towards the utilization of Computed Tomography (CT) scans, X-rays, & other imaging techniques to enhance visualization & obtain clearer disease stage images, rise in chronic respiratory conditions, and increasing introduction of advanced medical devices. For instance, in December 2022, Canon Inc. has revealed the introduction of its CXDI-Elite series of wireless digital radiography (DR2) devices, featuring the CXDI-720C Wireless sensor unit, targeting markets beyond Japan. Additionally, respiratory measurement devices is predicted to grow at the fastest CAGR during the forecast period owing to the physicians increasingly favor rapid and precise diagnostic methods, leading to a preference for tests such as pulse oximeters, growing demand for respiratory measurement devices, known as respirometers, which encompass spirometers, capnography, pulse oximeters, and peak flowmeters.
By application, asthma was the highest revenue-grossing segment in the global respiratory disease testing market in 2023 owing to the increasing prevalence of asthma and surge in partnerships & collaborations among market players. For instance, in January 2022, Highmark Health and Bosch have formed a research collaboration aimed at investigating the application of cutting-edge sensor technology and artificial intelligence (AI) for the detection of pediatric pulmonary conditions such as asthma. This partnership extends the tradition of utilizing innovative approaches in healthcare. Additionally, lung cancer is predicted to grow at the fastest CAGR during the forecast period owing to the growing advancement in imaging technologies utilized for lung cancer diagnosis, rise in the number of smokers, and increase in lung cancer cases.
By end-user, hospital was the highest revenue-grossing segment in the global respiratory disease testing market in 2023 owing to the increasing adoption and utilization of sophisticated respiratory diagnostic equipment such as X-ray machines & respiratory measurement instruments such as spirometers, pulse oximeters, & non-invasive ventilators, growing number of patients diagnosed with lung cancer, rising preference for hospital care, and expanding introduction of advanced medical systems. For instance, in July 2022, FUJIFILM Healthcare Corporation has introduced the FDR Cross, a versatile hybrid c-arm and portable x-ray solution designed for hospitals and ambulatory surgery centers (ASCs). This Two-in-One Fluoroscopy and Digital Radiography System enables wireless x-ray imaging similar to standard portable x-rays, accommodating various examinations such as table-top, cross-table, wheelchair, and standing chest exams by offsetting the x-ray tube from the built-in detector. Additionally, physician’s clinic is predicted to grow at the fastest CAGR during the forecast period owing to the rise in hospital-acquired infections has led patients to choose physician clinics for respiratory disease diagnosis. Physicians now favor in-house testing options over sending patients to external laboratories. This shift is expected to drive growth in this segment due to the convenience and personalized care offered by physician clinics.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing occurrence of respiratory conditions such as COPD, asthma, & various respiratory infections, rising demand for portable devices such as advanced spirometers & non-invasive ventilators, and increasing number of approvals granted by regulatory agencies. For instance, in June 2022, BD (Becton, Dickinson, and Company) has secured CE marking for its BD MAX Respiratory Viral Panel (RVP), an innovative molecular diagnostic assay that integrates screening for SARS-CoV-2, Influenza A + B, and Respiratory Syncytial Virus (RSV). This test requires only one nasal swab or nasopharyngeal swab sample to detect whether a patient is positive for COVID-19, influenza, or RSV. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the enhancements in healthcare infrastructure, heightened patient awareness of available diagnostic procedures, an uptick in respiratory disease prevalence, increased investments by industry players, and a surge in product introductions. For instance, in April 2023, QIAGEN has revealed plans to make its QIAstat-Dx syndromic testing solution accessible in Japan soon, featuring a SARS-CoV-2 Respiratory Panel capable of identifying over 20 pathogens from a single patient sample.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Growing introduction of novel respiratory disease testing products is predicted to boost the market growth during the forecast period. The respiratory system, crucial for human survival, serves the essential function of breathing and contributes significantly to maintaining the body's blood pH balance, eliminating harmful waste, and regulating temperature. Disruption of its normal functions occurs with respiratory diseases, often triggered by inhaling harmful substances, smoking, or unhealthy habits. For instance, in May 2022, UK's QuantuMDx Group Limited, known for its groundbreaking point-of-care diagnostic solutions, has introduced its latest offering, the Q-POC SARS-CoV-2, Flu A/B & RSV Assay, aimed at respiratory panel testing. This launch signifies the company's broadening of its multiplex capabilities and commitment to delivering swift point-of-care testing options to its clientele.
By product, imaging tests was the highest revenue-grossing segment in the global respiratory disease testing market in 2023 owing to the growing trend towards the utilization of Computed Tomography (CT) scans, X-rays, & other imaging techniques to enhance visualization & obtain clearer disease stage images, rise in chronic respiratory conditions, and increasing introduction of advanced medical devices. For instance, in December 2022, Canon Inc. has revealed the introduction of its CXDI-Elite series of wireless digital radiography (DR2) devices, featuring the CXDI-720C Wireless sensor unit, targeting markets beyond Japan. Additionally, respiratory measurement devices is predicted to grow at the fastest CAGR during the forecast period owing to the physicians increasingly favor rapid and precise diagnostic methods, leading to a preference for tests such as pulse oximeters, growing demand for respiratory measurement devices, known as respirometers, which encompass spirometers, capnography, pulse oximeters, and peak flowmeters.
By application, asthma was the highest revenue-grossing segment in the global respiratory disease testing market in 2023 owing to the increasing prevalence of asthma and surge in partnerships & collaborations among market players. For instance, in January 2022, Highmark Health and Bosch have formed a research collaboration aimed at investigating the application of cutting-edge sensor technology and artificial intelligence (AI) for the detection of pediatric pulmonary conditions such as asthma. This partnership extends the tradition of utilizing innovative approaches in healthcare. Additionally, lung cancer is predicted to grow at the fastest CAGR during the forecast period owing to the growing advancement in imaging technologies utilized for lung cancer diagnosis, rise in the number of smokers, and increase in lung cancer cases.
By end-user, hospital was the highest revenue-grossing segment in the global respiratory disease testing market in 2023 owing to the increasing adoption and utilization of sophisticated respiratory diagnostic equipment such as X-ray machines & respiratory measurement instruments such as spirometers, pulse oximeters, & non-invasive ventilators, growing number of patients diagnosed with lung cancer, rising preference for hospital care, and expanding introduction of advanced medical systems. For instance, in July 2022, FUJIFILM Healthcare Corporation has introduced the FDR Cross, a versatile hybrid c-arm and portable x-ray solution designed for hospitals and ambulatory surgery centers (ASCs). This Two-in-One Fluoroscopy and Digital Radiography System enables wireless x-ray imaging similar to standard portable x-rays, accommodating various examinations such as table-top, cross-table, wheelchair, and standing chest exams by offsetting the x-ray tube from the built-in detector. Additionally, physician’s clinic is predicted to grow at the fastest CAGR during the forecast period owing to the rise in hospital-acquired infections has led patients to choose physician clinics for respiratory disease diagnosis. Physicians now favor in-house testing options over sending patients to external laboratories. This shift is expected to drive growth in this segment due to the convenience and personalized care offered by physician clinics.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing occurrence of respiratory conditions such as COPD, asthma, & various respiratory infections, rising demand for portable devices such as advanced spirometers & non-invasive ventilators, and increasing number of approvals granted by regulatory agencies. For instance, in June 2022, BD (Becton, Dickinson, and Company) has secured CE marking for its BD MAX Respiratory Viral Panel (RVP), an innovative molecular diagnostic assay that integrates screening for SARS-CoV-2, Influenza A + B, and Respiratory Syncytial Virus (RSV). This test requires only one nasal swab or nasopharyngeal swab sample to detect whether a patient is positive for COVID-19, influenza, or RSV. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the enhancements in healthcare infrastructure, heightened patient awareness of available diagnostic procedures, an uptick in respiratory disease prevalence, increased investments by industry players, and a surge in product introductions. For instance, in April 2023, QIAGEN has revealed plans to make its QIAstat-Dx syndromic testing solution accessible in Japan soon, featuring a SARS-CoV-2 Respiratory Panel capable of identifying over 20 pathogens from a single patient sample.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Product, Application, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
Segmentation: Respiratory Disease Testing Market Report 2023 - 2034
Respiratory Disease Testing Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Respiratory Measurement Devices
- Blood Gas Test
- Imaging Tests
- Others
Respiratory Disease Testing Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Chronic Obstructive Pulmonary Disease
- Asthma
- Tuberculosis
- Lung Cancer
- Other
Respiratory Disease Testing Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Clinical Laboratories
- Hospital
- Physicians Clinic
- Other
Respiratory Disease Testing Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Respiratory Disease Testing Market: Product Estimates & Trend Analysis
8. Respiratory Disease Testing Market: Application Estimates & Trend Analysis
9. Respiratory Disease Testing Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Respiratory Disease Testing Market
12. Europe Global Respiratory Disease Testing Market
13. Asia Pacific Global Respiratory Disease Testing Market
14. Latin America Global Respiratory Disease Testing Market
15. MEA Global Respiratory Disease Testing Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- BIOMÉRIEUX
- Medtronic
- Koninklijke Philips N.V.
- ResMed
- Siemens Healthcare GmbH
- BD
- Carestream Health
- Abbott
- SDI Diagnostics
- Fisher & Paykel Appliances Ltd.
